Our focus

Orphan drugs

Biocodex develops drugs for patients with severe orphan diseases. In particular, we have launched an anti-epileptic drug DIACOMIT® (stiripentol) for the treatment of a rare and very severe form of childhood epilepsy.

Biocodex expertise in childhood epilepsy

After receiving marketing authorization in Europe in 2007, DIACOMIT® was approved in Canada and Japan in 2012, the United States and Switzerland in 2018, Australia in 2019 and Argentina in 2020. The drug is also distributed in many other countries through compassionate-use programs.
Currently, more than 5,500 patients benefit from this treatment in 55 countries.*

Building on this experience, Biocodex has developed a recognized expertise in pediatric neurology and set up a business unit focused on neurological drugs, some of them with orphan status.

In addition to developing our own products, we are pursuing long-term partnerships to distribute other innovative drugs, mainly in the European Union. Our goal is to provide treatments to unmet medical needs.

*Source: periodic benefit-risk evaluation report for active substance stiripentol from November-2019 to November-2020

Biocodex granted exclusivity on Kigabeq® distribution

In 2021, Biocodex was granted the exclusive rights to distribute Kigabeq® (vigabatrin) in most European countries on behalf of France’s Orphelia Pharma. This anti-epileptic drug is indicated in the treatment of a severe and rare epileptic disorder of the child.

Read the press release on Kigabeq® distribution and marketing agreement.